CFB
Complement factor B
As of the edition of 20 October 2026, CFB (complement factor B, UniProt P00751) has 4 drugs tested at it and 4 companies on the list, 0 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P00751
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 28
- Disease areas
- Blood and lymph; Pregnancy and women's health; Urinary and reproductive; Immune system; Eye; Nervous system; Cancer; Heart and blood vessels
- Registered trials of its drugs
- 48
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Stopped | 1 |
| Status not established | 1 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Iptacopan | Marketed | Phase 3 | Ends 2041 |
| HRS-5965 | Active | Phase 3 | none listed |
| Sefaxersen sodium | Stopped | Phase 2 | none listed |
| Sefaxersen | Status not established | Phase 3 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 1 |
| Engaged | 1 |
| Undetermined | 2 |
| Total on the list | 4 |
| Company | Route |
|---|---|
| Novartis | Route B |
The other 3 companies at CFB
In the product4 companies in all; 3 are not named here, and no score is.
See the 4 companies at CFB, ranked, with the facts behind eachRequest access. Nothing is shown until you do.